Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis

被引：0
|
作者：
Barrington, David [1 ]
Calhoun, Cody [1 ]
Haight, Paulina [1 ]
Tubbs, Crystal [1 ]
Cohn, David [1 ]
Bixel, Kristin [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [1] Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
    Barrington, David A.
    Haight, Paulina J.
    Calhoun, Cody
    Tubbs, Crystal
    Cohn, David E.
    Bixel, Kristin L.
    GYNECOLOGIC ONCOLOGY, 2021, 162 (03) : 626 - 630
  • [2] Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
    Barrington, D. A.
    Dilley, S. E.
    Smith, H. J.
    Straughn, J. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 23 - 23
  • [3] Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
    Barrington, David A.
    Dilley, Sarah E.
    Smith, Haller J.
    Straughn, J. Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (02) : 381 - 384
  • [4] Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
    Feng, Mingyang
    Chen, Yue
    Yang, Yang
    Li, Qiu
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [5] Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer
    Huo, Gengwei
    Song, Ying
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [6] Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China
    Liao, Xiaodong
    Wu, Yajing
    Lin, Dong
    Gu, Dian
    Luo, Shaohong
    Huang, Xiaoting
    Xu, Xiongwei
    Weng, Xiuhua
    Lin, Shen
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (05) : 881 - 889
  • [7] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF ADVANCED SECOND-LINE ENDOMETRIAL CANCER
    Yfantopoulos, N.
    Gountas, I
    Skroumpelos, A.
    Theiakos, K.
    Economou, O.
    Karokis, A.
    VALUE IN HEALTH, 2024, 27 (12) : S113 - S113
  • [8] Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer
    Van Le, Linda
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2022, 77 (05) : 275 - 276
  • [9] Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
    Makker, V
    Colombo, N.
    Casado Herraez, A.
    Santin, A. D.
    Colomba, E.
    Miller, D. S.
    Fujiwara, K.
    Pignata, S.
    Baron-Hay, S.
    Ray-Coquard, I
    Shapira-Frommer, R.
    Ushijima, K.
    Sakata, J.
    Yonemori, K.
    Kim, Y. M.
    Guerra, E. M.
    Sanli, U. A.
    McCormack, M. M.
    Smith, A. D.
    Keefe, S.
    Bird, S.
    Dutta, L.
    Orlowski, R. J.
    Lorusso, D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05): : 437 - 448
  • [10] Cost-effectiveness of atezolizumab plus chemotherapy for advanced/ recurrent endometrial cancer
    Huo, Gengwei
    Song, Ying
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
12345